aiwiki.page
English
Health / Diseases & Symptoms / alpha-one-antitrypsin-deficiency

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency is an inherited disorder that predisposes to emphysema, liver disease, and several uncommon inflammatory conditions.

36 keywords1 linked from8 not yet writtenWritten by AI
ProteinFibrosisCirrhosisGeneImmune SystemEnzymeInflammationEndoplasmic Reti…Alpha-1 An…

Alpha-1 antitrypsin deficiency is an inherited disorder in which the amount or function of alpha-1 antitrypsin, a protective blood protein, is reduced. Its principal consequences are increased susceptibility to pulmonary emphysema and, with certain genetic variants, injury to the liver. These complications arise through different mechanisms: insufficient functional protein permits destructive enzymes to damage lung tissue, whereas retention of abnormal protein within liver cells can cause cellular injury, fibrosis, and cirrhosis. Not everyone with a deficiency-associated genotype develops clinically important disease.

The disorder is caused by variants in the SERPINA1 gene and is one of the best-established inherited causes of chronic obstructive pulmonary disease (COPD). Its expression depends on genotype, age, tobacco exposure, and other environmental and biological factors. Recognition matters because the diagnosis can clarify otherwise unexplained respiratory or hepatic disease, identify at-risk relatives, and establish eligibility for disease-specific treatment in selected people with emphysema. The distinction between loss of protection in the lungs and toxic protein accumulation in the liver also determines why treatments effective for one organ do not necessarily benefit the other.

Protein function and mechanisms of tissue injury

Alpha-1 antitrypsin, also called alpha-1 proteinase inhibitor, is a circulating glycoprotein belonging to the serpin family of protease inhibitors. Most circulating protein is synthesized by hepatocytes, although several other cell types, including cells of the respiratory and immune systems, also produce it. Despite its historical name, its principal physiological target is not the digestive enzyme trypsin but neutrophil elastase. This enzyme is released by neutrophils during host defense and can digest components of the extracellular matrix, including elastin. Alpha-1 antitrypsin helps limit the damage that these enzymes can cause to neighboring tissues during inflammation.

Serpins inhibit target enzymes through a distinctive conformational mechanism. A protease attacks an exposed reactive-center loop on the inhibitor, triggering a structural rearrangement that traps the protease in a stable complex. Adequate delivery of functional alpha-1 antitrypsin to the lung therefore helps maintain a balance between proteolytic activity and antiprotease protection. Severe deficiency shifts that balance toward tissue destruction, particularly when inflammatory cells are repeatedly recruited by tobacco smoke, infection, or inhaled pollutants. The lungs’ very large gas-exchanging surface makes cumulative injury especially consequential.

Tobacco smoke acts through several interacting pathways. It increases inflammatory-cell recruitment and protease release, promotes oxidative stress, and can impair the inhibitory function of alpha-1 antitrypsin by oxidizing important amino-acid residues. Deficiency and smoking therefore interact rather than simply contributing independent, interchangeable risks. Destruction of alveolar walls reduces elastic recoil and the surface available for gas exchange, producing emphysema, air trapping, and eventually impaired oxygen transfer. This is fundamentally a loss-of-function mechanism: too little effective inhibitor reaches the tissue where it is needed.

The common severe-deficiency Z variant also creates a toxic gain of function. Its altered conformation favors the assembly of abnormal protein polymers, which are retained in the endoplasmic reticulum of hepatocytes instead of being efficiently secreted. Cellular protein-disposal systems, including proteasomal degradation and autophagy, remove part of this burden, but persistent accumulation can produce hepatocyte injury and fibrogenic responses. The resulting disorder is an important example of how the same genetic change can harm different organs through distinct biological processes.

These mechanisms explain a clinically important contrast between Z-associated deficiency and variants that produce no protein. Individuals with two null alleles can have extremely low circulating alpha-1 antitrypsin and substantial pulmonary risk, but they do not develop the characteristic hepatic storage injury because there is no abnormal protein to accumulate. Conversely, increasing the circulating concentration with replacement protein does not remove polymers already retained inside liver cells.

Genetic variants, nomenclature, and inheritance

SERPINA1 lies on chromosome 14 and encodes alpha-1 antitrypsin. The disorder is generally described as autosomal codominant: each inherited allele contributes to the protein phenotype and circulating concentration. Severe deficiency most often occurs when a person inherits two substantially deficient alleles, but heterozygous states can also modify disease susceptibility. Calling all heterozygotes unaffected “carriers” is therefore an oversimplification, particularly when smoking or another liver insult is present.

The traditional protease-inhibitor, or PI, nomenclature originated from the electrophoretic migration of alpha-1 antitrypsin variants. Common normal alleles belong to the M group; S and Z are the best-known deficiency alleles. Thus, PIMM usually denotes a normal phenotype, PIMZ a normal allele together with a Z allele, and PI*ZZ two Z alleles. The Z substitution is conventionally designated Glu342Lys in the mature protein, while the S substitution is Glu264Val. Numbering that includes the signal peptide gives different residue numbers, a distinction relevant when comparing laboratory reports or molecular publications.

PIZZ commonly produces circulating concentrations around 10–15% of normal, although measurements vary with laboratory method and physiological conditions. PISZ usually produces an intermediate deficiency, with considerable overlap between individuals; some concentrations fall below the traditional biochemical threshold used to define severe pulmonary risk. PI*MZ typically produces a more modest reduction. Null variants, often represented by Q0 designations, result in little or no detectable protein from the affected allele. Other rare variants impair secretion, alter inhibitory activity, or combine both effects.

For two PIMZ parents, each pregnancy has a 25% probability of a PIMM child, a 50% probability of a PIMZ child, and a 25% probability of a PIZZ child. These probabilities apply independently to each pregnancy. They describe inheritance, not the probability of developing emphysema or cirrhosis: clinical penetrance is incomplete, even among people with the same genotype. A genotype therefore establishes a biological predisposition rather than a fixed prediction of symptoms, age at onset, or survival.

The distinction between genotype and measured protein concentration is important. Alpha-1 antitrypsin is an acute-phase protein whose concentration rises during inflammation; pregnancy and estrogen exposure can also increase levels. A person with a deficiency allele can consequently have a result within a laboratory’s reference range under some circumstances. Conversely, a low concentration does not identify the underlying variants. Interpretation combines quantitative measurement with protein typing, targeted genetic testing, or sequencing. Genetic counseling addresses these distinctions, the range of possible clinical outcomes, and the implications of identifying a familial variant.

Discovery, distribution, and underrecognition

Alpha-1 antitrypsin deficiency was recognized in 1963 by Carl-Bertil Laurell and Sten Eriksson in Sweden. Their work linked a reduced or absent alpha-1 globulin band on serum protein electrophoresis with emphysema. This observation helped establish the protease–antiprotease model of lung injury and demonstrated that a specific inherited biochemical abnormality could predispose to chronic destructive lung disease. In 1969, Harvey Sharp and colleagues reported the association with childhood liver disease, broadening the condition from a pulmonary susceptibility disorder to a multisystem protein-folding disease.

The distribution of deficiency alleles is geographically uneven. The Z allele is particularly associated with northern European ancestry, whereas the S allele is relatively frequent in the Iberian Peninsula and some populations with related ancestry. Migration has distributed both alleles widely, and clinically important deficiency occurs across many ethnic and geographic groups. Ancestry can therefore inform population estimates but cannot reliably exclude the diagnosis in an individual. Rare variants also contribute a larger share of cases in some populations than a test limited to S and Z would detect.

Estimates of severe-deficiency prevalence depend on the population, genotype definition, and method of ascertainment. PIZZ is often estimated to occur in roughly one in 2,000–5,000 people in populations of European ancestry, but local frequencies differ substantially. PISZ and heterozygous states are more common in some regions. Estimates derived from allele frequencies are not equivalent to counts of diagnosed patients, nor do they directly measure the number who have clinically significant disease. Many genetically affected people remain asymptomatic or have not undergone testing.

A Swedish newborn-screening program conducted in 1972–1974 tested approximately 200,000 infants and identified a cohort with severe deficiency. Longitudinal follow-up supplied information unavailable from respiratory clinics, which disproportionately include symptomatic smokers. Such population-based observations showed that severe deficiency does not invariably lead to early disabling emphysema and clarified the importance of smoking exposure. They also demonstrated that childhood biochemical or clinical liver abnormalities do not uniformly predict severe adult liver disease.

Underrecognition remains a central feature of the disorder’s epidemiology. Respiratory manifestations overlap with ordinary smoking-related COPD and asthma, while hepatic manifestations can resemble other causes of chronic liver disease. Some patients are diagnosed only after years of respiratory symptoms, after a liver evaluation, or following identification of an affected relative. Professional guidance has consequently favored broad testing among people with COPD rather than restricting testing to those with unusually young onset or a classic emphysema distribution. Population screening is a separate policy question, involving test yield, consent, follow-up, and the consequences of identifying susceptibility before symptoms develop.

Pulmonary manifestations and clinical course

The characteristic pulmonary lesion is panacinar emphysema, in which destruction involves the acinus relatively uniformly and often predominates in the lower lung zones. This contrasts with the upper-zone centrilobular pattern commonly associated with smoking-related emphysema. The distinction is useful but not absolute: upper-lobe disease, mixed distributions, and substantial airway disease can occur in alpha-1 antitrypsin deficiency. Neither the absence of basal emphysema nor a history of cigarette smoking excludes a genetic contribution.

Clinical manifestations include progressive exertional shortness of breath, wheezing, reduced exercise tolerance, and sometimes chronic cough with sputum production. Symptoms may initially be attributed to asthma, recurrent bronchitis, physical deconditioning, or smoking alone. Severe deficiency can bring emphysema forward by decades, particularly in smokers, but age at presentation varies widely. Some people remain free of clinically important airflow obstruction into later adulthood, especially when they have avoided tobacco exposure. Childhood emphysema is unusual despite deficiency being present from birth.

Physiological assessment commonly shows persistent airflow obstruction, hyperinflation, and reduced diffusing capacity. Forced expiratory volume in one second, or FEV₁, measures airflow limitation but does not capture every dimension of tissue damage. Diffusing capacity can fall as alveolar surface and pulmonary capillary bed are lost, while exercise testing may reveal oxygen desaturation not evident at rest. Computed tomography can demonstrate emphysema before severe spirometric impairment and characterize its distribution. The relationship between imaging, lung function, and symptoms is therefore informative but not one-to-one.

Bronchiectasis, the permanent dilation of bronchi, occurs in some affected individuals and can contribute to daily sputum production, infection, and exacerbations. Its frequency varies across studies because definitions, imaging methods, and patient selection differ. Airway hyperresponsiveness and reversible components of obstruction may coexist with emphysema. Alpha-1 antitrypsin deficiency is therefore not simply an imaging diagnosis or a single pulmonary phenotype; individual patients can have different mixtures of parenchymal destruction and airway disease.

Progression depends strongly on exposure and baseline disease. Smoking is the most important established modifiable accelerator, while occupational dusts, fumes, and other inhaled irritants may add risk. Exacerbations can produce marked short-term deterioration and contribute to cumulative morbidity. In advanced disease, impaired gas exchange can cause chronic hypoxemia, pulmonary hypertension, and right-sided heart failure.

Natural-history estimates require attention to how patients were identified. Individuals detected because of respiratory symptoms generally have worse outcomes than relatives identified through family testing. Referral-center cohorts therefore cannot be assumed to represent all people with PI*ZZ. This ascertainment effect also helps explain why older descriptions emphasizing uniformly early respiratory disability differ from the broader range of outcomes seen in population and family studies.

Hepatic disease and uncommon systemic manifestations

Liver disease results chiefly from intracellular retention of polymer-forming alpha-1 antitrypsin variants, particularly Z. Its clinical range extends from transient childhood abnormalities to cirrhosis and liver failure in either childhood or adulthood. Hepatic and pulmonary severity are not tightly coupled: a person may have substantial liver disease with little respiratory impairment, or advanced emphysema without significant liver disease. The concentration measured in blood does not quantify the intracellular polymer burden or reliably stage hepatic injury.

In infancy, the disorder can present with cholestasis, prolonged jaundice, pale stools, hepatomegaly, and abnormal liver biochemical tests. Many affected infants improve clinically, whereas a minority develop progressive fibrosis, portal hypertension, or liver failure. The differential diagnosis includes biliary atresia and other metabolic or genetic causes of neonatal cholestasis. Recognition of alpha-1 antitrypsin deficiency does not eliminate the need to evaluate other conditions when the clinical pattern warrants it.

Adult liver disease may remain clinically silent until fibrosis is advanced. Possible presentations include persistent enzyme abnormalities, thrombocytopenia associated with portal hypertension, splenomegaly, ascites, or variceal bleeding. Older age, male sex, and coexisting metabolic or alcohol-related liver injury have been associated with greater disease burden in clinical cohorts. PI*MZ is increasingly recognized as a modifier of risk in people with other liver insults, rather than as a genotype that invariably causes primary liver disease by itself.

The characteristic tissue finding is the presence of periodic acid–Schiff-positive, diastase-resistant globules in hepatocytes, often prominent in periportal regions. Immunostaining can demonstrate alpha-1 antitrypsin within these inclusions. Their presence supports the diagnosis in the appropriate setting, but globule abundance does not directly measure the severity of fibrosis. Histological appearances also vary with age and sampling. Biopsy can help clarify unexplained liver disease or stage selected cases, but it is not required simply to establish an inherited deficiency that can be demonstrated by blood and genetic tests.

Cirrhosis increases the risk of hepatocellular carcinoma, a major form of liver cancer. In affected adults, clinical assessment therefore distinguishes the underlying genetic diagnosis from the separate questions of fibrosis stage, portal hypertension, and cancer risk.

A rare extrahepatic manifestation is necrotizing panniculitis, which can cause painful inflammatory subcutaneous lesions, ulceration, and oily drainage from liquefied fat. Tissue injury is thought to reflect insufficient control of local protease activity. Alpha-1 antitrypsin deficiency, especially the Z allele, is also associated with proteinase-3-antibody-positive granulomatosis with polyangiitis. These associations do not mean that most affected individuals develop either condition, but they explain why deficiency testing appears in some evaluations of otherwise unexplained panniculitis or particular forms of systemic vasculitis.

Diagnostic testing and assessment of organ involvement

The diagnosis combines measurement of circulating alpha-1 antitrypsin with identification of the responsible protein variants or genetic alleles. A quantitative serum blood test is commonly the starting point, but it is not sufficient in every case. Because the protein rises during inflammation, an apparently reassuring result during an infection or inflammatory episode can obscure an underlying deficiency. Concurrent assessment of inflammatory activity, repeat measurement under stable conditions, and molecular or phenotypic testing can resolve such discrepancies.

A concentration of approximately 11 μmol/L11\,\mu\text{mol/L}, often expressed as about 57 mg/dL57\,\text{mg/dL} with commonly used modern calibration, has traditionally served as a biochemical threshold relevant to severe deficiency and augmentation-treatment eligibility. This is not a sharp boundary separating people who will develop emphysema from those who will not. Historical assay standards produced different mass-concentration equivalents, so results must be interpreted using the laboratory method and reference information rather than by treating all published milligram-per-deciliter values as interchangeable.

Protein phenotyping by isoelectric focusing identifies variants according to their migration pattern. Targeted genotyping commonly tests for S and Z alleles; it is efficient for frequent variants but does not exclude rare deficient, dysfunctional, or null alleles. Expanded genotyping or SERPINA1 sequencing is useful when the measured concentration, phenotype, and initial genotype do not agree. Null alleles are especially important because an absent protein cannot create its own visible electrophoretic band. A laboratory result reported as negative for S and Z is therefore not equivalent to exclusion of every form of deficiency.

Clinical guidance generally includes testing adults with COPD, people with unexplained chronic liver disease, and selected patients with unexplained bronchiectasis, necrotizing panniculitis, or granulomatosis with polyangiitis. Some guidance also includes adults labeled as having asthma when persistent airflow obstruction is present. Once a disease-associated variant has been identified, testing relatives can detect affected individuals before substantial organ damage occurs. For family investigations, genotype-based methods are more informative than concentration measurement alone because they identify the inherited allele directly.

Assessment after diagnosis establishes whether organ disease is present and provides a baseline for follow-up. Pulmonary evaluation can include spirometry, lung volumes, diffusing capacity, oxygenation, and appropriately selected imaging. A baseline chest CT may characterize symptomatic disease or abnormal pulmonary physiology, but repeated CT solely for routine monitoring is not universally recommended. Radiation exposure and whether imaging would change management are relevant considerations.

Hepatic assessment includes liver enzymes, bilirubin, albumin, coagulation measures, platelet count, and imaging such as ultrasonography or elastography. Normal aminotransferases do not reliably exclude fibrosis. Interpretation therefore integrates laboratory trends, examination, imaging, and other liver-disease risk factors rather than relying on a single biomarker.

Respiratory management and transplantation

Most respiratory care follows established approaches to COPD, while also accounting for the inherited antiprotease defect. Avoidance of tobacco smoke is central because smoking substantially accelerates emphysema in severe deficiency. Clinical care also addresses occupational and environmental inhalational exposures, physical activity, nutritional status, and comorbid disease. These measures affect overall respiratory burden but do not correct the underlying SERPINA1 genotype or replace missing protein.

Inhaled bronchodilators are used to reduce airflow-related symptoms and improve exercise tolerance. Depending on the clinical phenotype, treatment may include long-acting muscarinic antagonists, long-acting beta agonists, or combinations. Inhaled corticosteroids have selected roles, particularly in patients with relevant exacerbation patterns or coexisting asthma features; they are not a universal treatment for the genetic deficiency itself. Acute exacerbations are managed according to their severity and suspected cause, with bronchodilator intensification and, when indicated, systemic corticosteroids or antibiotics.

Pulmonary rehabilitation combines exercise training, education, and other supportive interventions to address breathlessness, reduced conditioning, and activity limitation. Long-term supplemental oxygen has an established role in COPD with qualifying severe chronic resting hypoxemia, although it does not restore destroyed alveoli. Respiratory vaccination programs, including influenza and pneumococcal vaccination and other vaccines according to applicable guidance, aim to reduce preventable infections and their complications. Their role is supportive rather than a correction of antiprotease deficiency.

Advanced emphysema sometimes prompts consideration of procedures that reduce hyperinflation. Results from surgical lung-volume reduction have generally been less favorable or less durable in alpha-1 antitrypsin deficiency than in the upper-lobe-predominant emphysema groups that benefit most clearly in broader COPD trials. This does not make every intervention inappropriate: anatomical distribution, fissure integrity, collateral ventilation, exercise capacity, and procedural risk can influence selection for bronchoscopic or surgical approaches. The genetic diagnosis alone is not a complete procedural assessment.

Lung transplantation is an established option for selected people with end-stage respiratory disease. Selection incorporates physiological severity, functional impairment, expected benefit, comorbidities, and transplant-center criteria. Significant coexisting liver disease complicates evaluation and can occasionally lead to consideration of combined lung–liver transplantation in highly selected cases.

A transplanted lung does not correct the recipient’s hepatic production of alpha-1 antitrypsin, so the circulating deficiency persists after lung transplantation. Nevertheless, removal of severely damaged lungs can substantially improve respiratory function. Evidence about routine continuation or initiation of augmentation therapy after transplantation is limited, and practice varies. Transplant outcomes also depend on factors shared with other indications, including infection, rejection, and long-term immunosuppression, rather than solely on the original genetic disorder.

Intravenous augmentation therapy and its evidence base

Intravenous augmentation therapy supplies purified alpha-1 proteinase inhibitor derived from pooled human plasma. Its purpose is to increase circulating and pulmonary concentrations of functional inhibitor and reduce ongoing protease-mediated destruction. A widely used regimen is 60 mg/kg60\,\text{mg/kg} intravenously once weekly. It is a disease-specific treatment for selected patients with severe deficiency and established emphysema, not a cure: it neither changes the inherited genotype nor regenerates lost alveolar tissue.

Eligibility differs among jurisdictions, product labels, and clinical guidelines. Common considerations include confirmed severe biochemical deficiency, a qualifying genotype, evidence of emphysema with airflow obstruction, and absence of current smoking. The airflow-obstruction range for which evidence or recommendations are strongest varies across guidance. Treatment is not routinely supported for PI*MZ individuals with COPD because their degree of deficiency and the available evidence do not establish the same benefit. A genotype label without an accompanying clinical and biochemical assessment is insufficient to determine eligibility.

The principal randomized evidence concerns preservation of lung tissue measured by CT densitometry. In the RAPID trial, published in 2015, 180 participants were assigned to weekly augmentation therapy or placebo for two years. CT lung-density decline measured at total lung capacity was slower in the treatment group: approximately 1.451.45 versus 2.19 g/L2.19\,\text{g/L} per year. However, the prespecified analysis combining scans at total lung capacity and functional residual capacity did not reach conventional statistical significance. These distinctions matter when interpreting the trial as evidence of structural benefit rather than as an unequivocally positive result across every planned analysis.

CT densitometry measures loss of lung tissue more directly than spirometry, but it functions as a surrogate endpoint. Randomized trials have not established comparably clear benefits for mortality, exacerbation frequency, or FEV₁ decline. An open-label extension of RAPID supported the interpretation that treatment can slow subsequent density loss but does not recover tissue lost before treatment begins. Observational registries have reported additional associations, including survival differences, but such findings are more vulnerable to selection bias and confounding than results from a randomized controlled trial.

Practical limitations include repeated intravenous administration, cost, access, and dependence on plasma-derived products. Infusion reactions and hypersensitivity can occur. Product-specific precautions apply, including considerations involving severe immunoglobulin A deficiency and anti-IgA antibodies. Donor screening and manufacturing steps reduce infectious risk, but the safety assessment remains specific to each product and recipient.

Augmentation does not treat the hepatic storage mechanism. Increasing circulating normal protein does not remove mutant protein from hepatocytes, and the therapy is not indicated solely to prevent or reverse alpha-1-antitrypsin-associated liver disease. Experience in severe deficiency-associated panniculitis suggests benefit in some cases, but that evidence comes mainly from reports and small series rather than a trial program comparable to the pulmonary studies.

Liver-directed treatment and emerging molecular therapies

Established management of alpha-1-antitrypsin-associated liver disease addresses the consequences of hepatic injury and the presence of additional liver disorders. Clinical surveillance is determined by age, disease stage, and findings such as portal hypertension or cirrhosis. Management of ascites, varices, impaired synthetic function, and hepatocellular carcinoma risk generally follows principles used for chronic liver disease of other causes. Avoidance of additional hepatic injury is relevant, but no conventional medical treatment has been shown to reliably remove the intracellular Z-protein burden and prevent all progression.

Liver transplantation is the definitive organ-replacement treatment for advanced hepatic disease. Because the liver produces most circulating alpha-1 antitrypsin, transplantation from a donor with normal production usually restores circulating concentrations toward the donor’s normal phenotype. It therefore differs fundamentally from lung transplantation, which replaces the damaged target organ without correcting the principal source of the deficient protein. Liver transplantation does not reverse pre-existing emphysema, so pulmonary status remains important during evaluation and subsequent care.

The distinction between toxic accumulation and systemic deficiency has shaped experimental treatment. One approach uses RNA interference to reduce production of mutant alpha-1 antitrypsin in hepatocytes. Fazirsiran, an investigational small-interfering-RNA therapy, produced substantial reductions in hepatic Z-protein burden in an early study published in 2022. That study involved a small number of adults and reported changes in histological and biochemical measures; such results do not by themselves establish prevention of liver failure, cancer, transplantation, or death. Larger controlled studies are needed to determine durable clinical benefit and safety.

Suppressing hepatic production creates a particular therapeutic trade-off: reducing the toxic protein can also reduce the circulating antiprotease supply. Development programs therefore have to evaluate hepatic benefit alongside pulmonary consequences. This challenge has encouraged interest in combinations that reduce mutant-protein production while supplying functional protein by another route. It also illustrates why a successful liver-targeted molecular intervention cannot automatically be assumed to treat the whole disorder.

Other investigational strategies include molecules intended to prevent polymer formation, compounds that improve folding or secretion, and interventions that enhance intracellular protein clearance. Their desired effects differ: blocking polymerization may reduce hepatocyte injury, while restoring secretion of a functional protein could potentially address both liver accumulation and pulmonary deficiency. Demonstrating that a compound increases blood protein concentration is not sufficient unless the secreted protein retains appropriate inhibitory function and the treatment does not worsen intracellular toxicity.

Gene therapy and gene-editing approaches seek either to provide sustained production of functional alpha-1 antitrypsin or to correct the disease-associated sequence. Important obstacles include achieving adequate long-term expression, controlling immune responses, reaching the relevant cells, and establishing safety. Pulmonary trials also face the slow and variable course of emphysema, which makes clinically meaningful differences difficult to demonstrate over short periods. Liver-directed trials must distinguish reductions in stored protein from actual reversal of fibrosis or prevention of decompensation. Across these approaches, a molecular or imaging response remains distinct from demonstrated improvement in organ function or long-term clinical outcomes.